Metastatic Melanoma
Advanced Melanoma Immunotherapy Landscape: Positioning Novel and Emerging Agents
This activity is supported by an educational grant from Merck & Co., Inc.
Melanoma Insights: Focus on High-Risk Early-Stage to Advanced Disease Management
This activity is supported by an educational grant from Merck & Co., Inc.
Iovance submits EU marketing authorization for lifileucel for advanced melanoma
Iovance Biotherapeutics has submitted a marketing authorization application to the European Medicines Agency for lifileucel to treat advanced melanoma, the company announced in a press release.
‘There may be a role’ for frontline lifileucel plus pembrolizumab in advanced melanoma
CHICAGO — A front-line treatment regimen including lifileucel and pembrolizumab produced ongoing durable responses in some patients with unresectable or metastatic melanoma, according to findings presented at ASCO Annual Meeting.
Not all treatments created equal: Identifying barriers to immunotherapy for melanoma
Immunotherapy is a life-saving treatment for melanoma, but not all individuals have access to this treatment, according to a study.
Alpha-9 Oncology doses first subject in phase 1 study for new melanoma diagnostic agent
The first participant has been dosed in the phase 1 study evaluating Ga-A9-3202 for locally advanced or metastatic melanoma imaging, Alpha-9 Oncology announced in a press release.
Lifileucel approval the start of a ‘glorious future’ for cell therapy in solid tumors
It took more than 35 years for tumor-infiltrating lymphocytes, which Steven A. Rosenberg, MD, PhD, and colleagues first reported on in 1988 for the treatment of advanced melanoma, to progress enough to gain FDA approval.
FDA grants accelerated approval to immunotherapy for unresectable or metastatic melanoma
The FDA has granted accelerated approval to a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma.
Oncology Innovations: LAG3 Inhibition in Melanoma Treatment
This activity is supported by an independent educational grant from Bristol Myers Squibb.
Melanoma Monday: Vitamin D levels affect response, machine learning predicts recurrence
Today is Melanoma Monday.